Case Control Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 28, 2019; 25(48): 6902-6915
Published online Dec 28, 2019. doi: 10.3748/wjg.v25.i48.6902
Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma
Yong-Lian Zeng, Zhen-Ya Guo, Hui-Zhao Su, Fu-Di Zhong, Ke-Qing Jiang, Guan-Dou Yuan
Yong-Lian Zeng, Zhen-Ya Guo, Hui-Zhao Su, Fu-Di Zhong, Ke-Qing Jiang, Guan-Dou Yuan, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China
Author contributions: Zeng YL and Yuan GD designed the research; Guo ZY, Zhong FD, Jiang KQ and Su HZ performed the research; Zeng YL, Guo ZY and Yuan GD analyzed the data; Zeng YL and Yuan GD wrote the paper.
Institutional review board statement: This study was reviewed and approved by the First Affiliated Hospital of Guangxi Medical University Ethics Committee.
Informed consent statement: All patients in our study provided informed consent.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Guan-Dou Yuan, M.D., Ph.D., Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, Nanning 530021, Guangxi, China. yuan25958282@163.com
Received: September 29, 2019
Peer-review started: September 29, 2019
First decision: November 10, 2019
Revised: November 27, 2019
Accepted: December 13, 2019
Article in press: December 13, 2019
Published online: December 28, 2019
Core Tip

Core tip: Previous studies have found that lncRNA cancer susceptibility candidate 9 (CASC9) can promote the survival of hepatocellular carcinoma (HCC) cells through AKT ions, but it is not clear whether lncRNA CASC9 can be used as a clinical indicator of diagnosis and prognosis in patients with HCC. This study confirmed that lncRNA CASC9 can be used as a potential prognostic and diagnostic indicator in patients with HCC and it may be a potential therapeutic target for HCC.